ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

19 Aug 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

12 Aug 2025 13:05:01 By Nasdaq GlobeNewswire

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

05 Aug 2025 05:00:01 By Nasdaq GlobeNewswire

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

30 May 2025 05:00:21 By Nasdaq GlobeNewswire

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

20 May 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

13 May 2025 05:00:01 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

08 May 2025 05:30:00 By Nasdaq GlobeNewswire

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

02 May 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

25 Apr 2025 10:10:00 By Nasdaq GlobeNewswire

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

25 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate

07 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

06 Mar 2025 13:01:00 By Nasdaq GlobeNewswire

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

05 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

27 Feb 2025 05:00:01 By Nasdaq GlobeNewswire

ALX Oncology to Host Virtual R&D Day on March 5, 2025

18 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

23 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

22 Jan 2025 13:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

22 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

21 Jan 2025 14:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 05:00:01 By Nasdaq GlobeNewswire